IGF-1 DES
Investigación limitadaTruncated IGF-1 Analog | Localized Muscle Growth
IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids.
Datos moleculares y de investigación
- Peso molecular
- ~7,000 Da
- Vida media
- 20-30 minutes
- Objetivos primarios
- igf1, mtor
- Rutas (investigación)
- injectable
- Almacenamiento
- Lyophilized: -20C. Reconstituted: 2-8C, use within 7 days (BAC water)
Overview
IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation – it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.
Mechanism of action
IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.
Key research findings
- Approximately 10x more potent than native IGF-1
- 100% bioactive – does not bind to IGF binding proteins
- Extremely short half-life enables localized, site-specific action
- Promotes satellite cell activation for muscle hyperplasia
- Minimal systemic exposure compared to IGF-1 LR3
Research applications
Muscle Growth
- Localized Hypertrophy — Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.
- Hyperplasia — Stimulates satellite cell proliferation and differentiation, potentially creating new muscle fibers.
- Recovery — Accelerates local tissue recovery in the injected muscle group after training.
Tissue Repair
- Local Tissue Repair — Promotes repair and regeneration at the injection site through IGF-1R activation.
Preguntas frecuentes sobre IGF-1 DES
Why is IGF-1 DES injected directly into muscles?+
IGF-1 DES has a 20-30 minute half-life and doesn't bind IGF binding proteins, making it 10x more potent but short-acting. Direct intramuscular injection confines its activity to the targeted muscle immediately post-workout, enabling localized hypertrophy without systemic IGF-1 excess.
Will IGF-1 DES cause hypoglycemia?+
Yes. IGF-1 DES lowers blood glucose by promoting glucose uptake into muscle tissue. You must consume 20-40g of fast carbohydrates immediately after injection. Monitor blood glucose early in use and never inject before sleep due to overnight hypoglycemia risk.
Can I use IGF-1 DES if I'm on a keto diet?+
Not safely. The mandatory carbohydrate intake after IGF-1 DES injection will break ketosis. If keto is your goal, use alternatives like GH or ipamorelin instead. The post-injection carbs are non-negotiable for safety.
Does IGF-1 DES cause cancer risk?+
IGF-1 promotes cell proliferation, and elevated systemic IGF-1 is linked to multiple cancers in the UK Biobank study. DES minimizes systemic exposure through its short half-life and local injection, but cancer risk remains a theoretical concern with any IGF-1 product.
References
- [1]The isolation and characterization of a naturally occurring truncated form of IGF-I in human brainBiochemical and Biophysical Research Communications
- [2]Des(1-3)IGF-I: A truncated form of insulin-like growth factor-I that has greatly enhanced activity in promoting growthJournal of Molecular Endocrinology
- [3]Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated ratsBiochemical Journal
- [4]Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK BiobankCancer Research
Péptidos relacionados
ACE-031
Emerging researchMyostatin Inhibitor | Experimental Muscle Growth
ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to an IgG1 Fc domain.
CJC-1295
In clinical trialsAnálogo de GHRH de larga duración
CJC-1295 es un análogo sintético de la hormona liberadora de hormona del crecimiento (GHRH) diseñado para una vida media dramáticamente extendida, estudiado por su capacidad de elevar los niveles de hormona del crecimiento e IGF-1.
CJC-1295 with DAC
Well studiedLong-Acting Growth Hormone Releasing Hormone Analog | Extended Release
Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.
CJC/IPA Protocol
Well studiedGHRH/GHRP Combination | Growth Hormone Optimization
A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms.